Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr 15;2009(2):CD006996.
doi: 10.1002/14651858.CD006996.pub2.

Pimozide for tics in Tourette's syndrome

Tamara Pringsheim  1 , Connie Marras
Affiliations

Pimozide for tics in Tourette's syndrome

Tamara Pringsheim et al. Cochrane Database Syst Rev. .

Abstract

Background: Neuroleptic drugs with potent D-2 receptor blocking properties have been the traditional treatment for tics caused by Tourette Syndrome. Pimozide is the most studied of these. Use of these medications is declining because of concerns about side effects, and new atypical neuroleptics are now available. The true benefit and risks associated with pimozide compared to other drugs is not known.

Objectives: To evaluate the efficacy and harms of pimozide in comparison to placebo or other medications in the treatment of tics in Tourette Syndrome.

Search strategy: We cross-referenced pimozide and its proprietary names with Tourette Syndrome and its derivations, as MeSH headings and as text words, and searched the Cochrane Movement Disorders Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 4), MEDLINE (1950-April 2007), and EMBASE (1980-April 2007). Reference lists of relevant articles were reviewed for additional trials.

Selection criteria: All randomized, controlled, double blind studies comparing pimozide to placebo or other medications for the treatment of tics in Tourette Syndrome were considered for inclusion in this review. Both parallel group and crossover studies of children or adults, at any dose and for any duration, were included.

Data collection and analysis: Data was abstracted independently by two authors onto standardized forms and disagreements were resolved by discussion.

Main results: Six randomized controlled trials were included (total 162 participants, age range 7 to 53 years). Pimozide was compared with: placebo and haloperidol (two trials), placebo (one trial), haloperidol (one trial), and risperidone (two trials). Methodological quality was rated 'fair' for all studies. Studies used different outcome measurement scales for assessing tic severity and adverse effects. Significant clinical heterogeneity made meta-analysis inappropriate. Pimozide was superior to placebo in three studies, though it caused more side effects than placebo in one of these. Pimozide was inferior to haloperidol in one of three studies (the other two showed no significant difference between the drugs), which also showed significantly fewer side effects associated with pimozide. No significant differences between pimozide and risperidone were detected.

Authors' conclusions: Pimozide is an effective treatment for tics in Tourette Syndrome, though the number of trials comparing its effect to placebo and other drugs is limited. Trials of longer duration (minimum six months) are needed to investigate the longer-term effects of pimozide compared to atypical neuroleptics. Future trials should use the Yale Global Tic Severity Scale to assess the main outcome measure, and quantify adverse events with the Extrapyramidal Symptoms Rating Scale.

PubMed Disclaimer

Conflict of interest statement

None

Update of

  • doi: 10.1002/14651858.CD006996

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Bruggeman 2001 {published data only}
    1. Bruggeman R, Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, et al. Risperidone versus pimozide in Tourette's disorder: a comparative double‐blind parallel group study.. Journal of Clinical Psychiatry 2001;62(1):50‐56. - PubMed
Gilbert 2004 {published data only}
    1. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double‐blind, crossover trial.. Journal of the American Academy of Child and Adolescent Psychiatry 2004;43(2):206‐214. - PubMed
Ross 1978 {published data only}
    1. Ross MS, Moldofsky. Comparison of Pimozide with Haloperidol in Gilles de la Tourette Syndrome. The Lancet 1977 January;1:103. - PubMed
    1. Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's Syndrome. American Journal of Psychiatry 1978;135(5):585‐587. - PubMed
Sallee 1997 {published data only}
    1. Sallee F, Dougherty D, Sethuraman G, Vrindavanam N. Prolactin monitoring of halodperidol and pimozide treatment in children with Tourette's syndrome. Biological psychiatry 1996;40:1044‐1050. - PubMed
    1. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. American Journal of Psychiatry 1997;154(1057‐1062). - PubMed
Shapiro 1984 {published data only}
    1. Shapiro AK, Shapiro E. Controlled study of pimozide vs placebo in Tourette's syndrome. Journal of the American Academy of Child Psychiatry 1984;23(2):161‐173. - PubMed
Shapiro 1989 {published data only}
    1. Shapiro E, Shapiro A, Fulop G, Hubbard M, Mandeli J, et al. Controlled study of haloperidol, pimozide, and placebo in the treatment of Gilles de la Tourette's Syndrome. Archives of General Psychiatry 1989;46:722‐730. - PubMed

Additional references

APA 2000 [Computer program]
    1. American Psychiatric Association. 307.23 Tourette Disorder, Diagnostic and Statistical Manual of Mental Disorders, Text Revision. American Psychiatric Publishing Inc, 2000.
Correll 2004
    1. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of 1 year studies.. American Journal of Psychiatry 2004;161:414‐425. - PubMed
Fedorowicz 2005
    1. Fedorowicz VJ, Fombonne E. Metabolic side effects of atypical antipsychotics in children: a literature review.. Journal of Psychopharmacology 2005;19(5):533‐550.. - PubMed
Freeman 1989
    1. Freeman PR. The performance of the two‐stage analysis of two‐treatment, two‐period crossover trials.. Stat Med 1989;8(12):1421‐32. - PubMed
Grizzle 1965
    1. Grizzle JE. The two‐period change over design and its use in cliniccal trials.. Biometrics 1965;21:467‐480. - PubMed
Harris 2001
    1. Harris R, Helfand M, Woolf S, Lohr K, Mulrow C, et al. Current methods of the US Preventive services task force. American Journal of Preventive Medicine 2001;20(3S):21‐35.. - PubMed
Khalifa 2005
    1. Khalifa N, Knorring AL. Tourette syndrome and other tic disorders in a total population of children: clinical assessment and background.. Acta Pediatrica 2005;94(11):1608‐1614. - PubMed
Leckman 1989
    1. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, et al. The Yale Global Tic Severity Scale: initial testing of a clinician rated scale of tic severity.. Journal of the American Academy of Child and Adolescent Psychiatry 1989;28(4):566‐73. - PubMed
Robertson 2000
    1. Robertson MM, Stern J. Gilles de la Tourette syndrome: Symptomatic treatment based on evidence.. European child and adolescent psychiatry 2000;9(1):60‐75. - PubMed
Storch 2007
    1. Storch EA, Murphy TK, Fernandez M, Krishnan M, Geffken GR, et al. Factor analytic study of the Yale Global Tic Severity Scale. Psychiatry Research 2007;149(1‐3):231‐7. - PubMed

Publication types

MeSH terms